MSX3 是一种具有口服活性的选择性 A2a 腺苷受体拮抗剂,也是 MSX2 (MS-F26912) 的前药,可降低小鼠特定表位的 Tau 过度磷酸化而不改变其总 Tau 水平、Tau 片段或 Tau 聚集情况,增强空间记忆,调控与努力相关的决策行为,逆转 D2 拮抗剂诱导的杠杆按压抑制、Chow 饲料摄入量增加、高障碍臂选择减少及反应潜伏期延长,并轻度减弱 D1 拮抗剂诱导的效应,因此可用于 Tau 病(阿尔茨海默病相关)、抑郁症及帕金森综合征的研究。
产品编号: MS-S30513 CAS No.: 261717-23-1 分子式: C21H21N4Na2O7P 分子量: 518.37
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

MSX3 是一种具有口服活性的选择性 A2a 腺苷受体拮抗剂,也是 MSX2 (MS-F26912) 的前药,可降低小鼠特定表位的 Tau 过度磷酸化而不改变其总 Tau 水平、Tau 片段或 Tau 聚集情况,增强空间记忆,调控与努力相关的决策行为,逆转 D2 拮抗剂诱导的杠杆按压抑制、Chow 饲料摄入量增加、高障碍臂选择减少及反应潜伏期延长,并轻度减弱 D1 拮抗剂诱导的效应,因此可用于 Tau 病(阿尔茨海默病相关)、抑郁症及帕金森综合征的研究。

生物实验数据

生物活性 MSX3 is an orally active, selective A2a adenosine receptor antagonist and a prodrug of MSX2 (MS-F26912) that reduces Tau hyperphosphorylation at specific epitopes in mice without altering total Tau levels, Tau fragments, or Tau aggregation, enhances spatial memory, modulates effort-related decision-making behavior, reverses D2 antagonist-induced suppression of lever pressing, increased Chow feed intake, reduced high-effort arm selection, and prolonged response latency, and mildly attenuates D1 antagonist-induced effects, and can therefore be used for research on tauopathies (Alzheimer's disease-related), depression, and parkinsonism.
IC50 & Target

A2AR

 

体内研究
(In Vivo)

MSX3 (0.3 g/L;通过饮用水口服;每日) 可使 THY-Tau22 小鼠的空间记忆恢复正常,并显著降低其海马区 Tau 蛋白在 Ser262、Ser404 和 Ser214 表位的过度磷酸化水平。
MSX3 (腹腔注射;单次;测试前 20 分钟;0.75-3.0 mg/kg) 在大鼠中可剂量依赖性逆转 Haloperidol (MS-R31640) 诱导的努力相关选择和反应潜伏期损伤,其中 3.0 mg/kg 剂量可将 T 迷宫表现完全恢复至溶媒对照组水平;单独给予 3.0 mg/kg 剂量时,对 T 迷宫表现无显著影响。

Animal Model: C57Bl6/J THY-Tau22 (male, 6 months of age at treatment initiation, Alzheimer's disease tauopathy model)
Dosage: 0.3 g/l; 1.4 mg per mouse daily
Administration: p.o.; daily
Result: Increased Y-maze discrimination index significantly relative to water-treated THY-Tau22 mice (P = 0.05, one-way ANOVA) and normalized to wild-type levels.
Reduced acidic Tau isovariants, indicating decreased global Tau phosphorylation.
Reduced Tau phosphorylation at Ser262 (P < 0.01), Ser404 (P < 0.05), and Ser214 (P < 0.05) relative to water-treated THY-Tau22 mice.
Left total Tau protein levels, Tau proteolytic fragments, and sarkosyl-insoluble Tau unchanged.
Showed no significant differences in body weight gain or body temperature relative to water-treated groups.
Animal Model: Sprague-Dawley (adult male, drug-naive, 290-340 g at study start, food-deprived to 85% free-feeding body weight, psychomotor/motivational impairment induced via i.p. haloperidol)
Dosage: 0.75 mg/kg (co-administered with haloperidol); 1.5 mg/kg (co-administered with haloperidol); 3.0 mg/kg (co-administered with haloperidol); 3.0 mg/kg (administered alone)
Administration: i.p.; single dose; 20 min before testing
Result: Produced a dose-related increase in selection of the high-density barrier arm relative to haloperidol plus vehicle-treated rats (p<0.01).
Completely reversed haloperidol-induced reduction in high-density arm selection at 3.0 mg/kg, with rats choosing the barrier arm at levels equivalent to vehicle control.
Reduced haloperidol-induced increased response latency significantly at 0.75 mg/kg (p<0.001) and at 1.5 and 3.0 mg/kg (p<0.05) relative to haloperidol plus vehicle.
Showed no significant effect on high-density arm selections (mean 28.6 vs. vehicle mean 28.0; t=-1.0, df=4, n.s.) when administered alone at 3.0 mg/kg.
Showed no significant effect on average run latency (mean 3.33 vs. vehicle mean 3.67; t=2.4, df=4, n.s.) when administered alone at 3.0 mg/kg.

化学信息

分子量 518.37
分子式 C21H21N4Na2O7P
CAS No. 261717-23-1

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础